Hutchison China MediTech (HCM) is an innovative China-based biopharmaceutical company targeting the global market for novel, highly selective oral oncology and immunology drugs. Its established commercial platform business continues to expand its outreach.
Investment summary
Hutchison China MediTech (HCM) has built a substantial pipeline of tyrosine kinase inhibitor drugs. Launch of Elunate (fruquintinib capsules) in China in 2018 serves as validation of the R&D efforts. Key late-stage asset surufatinib met the primary endpoint of PFS in non-pancreatic NET and pancreatic NET, translating into earlier than expected China NDA submissions for both indications (epNET filed in November, pNET to file H120). Surufatinib could be HCM’s first unpartnered asset to launch (late 2020). The US FDA has also granted two fast track designations for surufatinib in epNET and pNET (NDA to file in late 2020). We forecast further product launches in 2021/22 (China launch of savolitinib in MET exon 14 deletion NSCLC) and global launch of savolitinib in EGFR-resistant NSCLC in combination with Tagrisso; timing depending on interim data from the SAVANNAH trial. Elunate has been included in China’s NRDL, which significantly increases the addressable market.
HCM’s profitable Chinese healthcare business continues to benefit from the fast-growing domestic market, while the clinical, regulatory and technological environments are highly conducive to novel drug development. In the longer term, as the oncology pipeline comes to fruition we expect HCM to become a major oncology company globally.
